Oral melatonin has no effect on appetite in advanced cancer

March 16, 2013
Oral melatonin has no effect on appetite in advanced cancer
Oral melatonin does not improve appetite, weight, or quality of life for patients with cachexia due to advanced cancer, according to research published online Feb. 25 in the Journal of Clinical Oncology.

(HealthDay)—Oral melatonin does not improve appetite, weight, or quality of life for patients with cachexia due to advanced cancer, according to research published online Feb. 25 in the Journal of Clinical Oncology.

In an effort to determine whether may be associated with appetite improvement in patients with cancer cachexia, Egidio Del Fabbro, M.D., of the University of Texas MD Anderson Cancer Center in Houston, and colleagues performed a randomized, double-blind, 28-day trial of melatonin 20 mg versus placebo in 48 patients with advanced lung or .

This study was closed for futility after the interim analysis was performed and results suggested that, even with a larger sample size, the results were not likely to change. No significant difference was observed between melatonin- and placebo-treated groups with regard to appetite, other symptoms, weight, score on the Functional Assessment of Anorexia/Cachexia Therapy questionnaire, toxicity, or survival.

"In cachectic patients with advanced lung or gastrointestinal cancer, oral melatonin 20 mg at night did not improve appetite, weight, or quality of life compared with placebo," the authors write. "More research is required to determine whether melatonin has a role in the supportive care of patients earlier in their disease ."

Explore further: Heavy lifting for cancer research

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Heavy lifting for cancer research

February 9, 2012

Many patients with advanced cancer suffer from cachexia, a condition also called body-wasting or wasting syndrome, which causes significant weight loss, extreme fatigue and reduces quality of life.

Prophylaxis with apixaban feasible for cancer patients

March 29, 2012

(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is ...

L-carnitine does not reduce cancer-related fatigue

September 18, 2012

(HealthDay)—Patients with invasive malignancies who take L-carnitine supplements do not experience a reduction in fatigue, pain, or depression, according to research published online Sept. 17 in the Journal of Clinical ...

Making headway on beta-blockers and sleep

September 28, 2012

Over 20 million people in the United States take beta-blockers, a medication commonly prescribed for cardiovascular issues, anxiety, hypertension and more. Many of these same people also have trouble sleeping, a side effect ...

Parenteral hydration no benefit for cancer care in hospices

November 28, 2012

(HealthDay)—For patients with advanced cancer in hospices, providing parenteral saline (1 liter per day) does not improve symptoms associated with dehydration, quality of life, or overall survival compared with placebo, ...

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.